Objectives Thalassaemia is a genetic disorder of haemoglobin synthesis characterised by life-long chronic anaemia. Although the endocrine and cardiac complications of thalassaemia are well-studied, ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its ex vivo gene therapy for the rare blood disorder beta thalassaemia. The EU regulator has ...

Treatments are the same as cancer sufferers but they don't receive the same support, a mother says.

The facility, funded through Rs 2.75 crore in corporate social responsibility (CSR) contributions from Aditya Birla Capital ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

saying it was "untenable" to bring gene therapies to market there after failing to reach a pricing agreement with Germany for its beta thalassaemia treatment Zynteglo. There's no word on pricing ...

As the MRI with its building sprawl over five acres, a stone’s throw from Borella junction, celebrates its 125th anniversary, Director Dr. Suranga Dolamulla journeys back in time to its humble origins ...

Family history of IDA (which may indicate inherited disorders of iron absorption23), haematological disorders (eg, thalassaemia), telangiectasia and bleeding disorders should be sought. A history of ...